HBV drug well tolerated, reduces surface antigens in phase 2 trial

Patients with hepatitis B treated with an investigational RNAi drug experienced reduced levels of surface antigens across different dose levels, according to research presented at The Digital International Liver Congress.The drug, called VIR-2218 (VIR Biotechnology), is an X-targeting RNAi therapeutic designed to silence all HBV transcripts across all 10 HBV genotypes.“GaINAc conjugation allows targeted delivering to the liver through subcutaneous administration and prolongs the pharmacodynamic effects of VIR-2218, thereby allowing monthly dosing,” Edward Gane, MD, from theRead More

Share on facebook
Share on twitter
Share on linkedin